Resources

In this blog, BIA member Brainomix, following its series C round, answers questions on the company's origins and future trajectory.

Imperial Incubator and Imperial College Healthcare NHS Trust have announced new partnerships with ARC West London, designed to support innovators across AI, life sciences, robotics and digital industries to scale, further bolstering the thriving West London life sciences ecosystem.

Oligos explainer: A new frontier in precision medicine, highlights the transformative potential of oligonucleotide therapies. These precision medicines, which use short DNA or RNA molecules to target specific genes, offer groundbreaking solutions for diseases previously deemed untreatable, from rare genetic disorders to cancer.

Emerson partners with biopharmaceutical companies to drive innovation, efficiency, and compliance in life sciences manufacturing through cutting-edge automation and process expertise. As a new BIA member, Emerson is committed to helping manufacturers streamline production, ensure product quality, and accelerate time to market for life-saving therapies. In this blog, David introduces the company's latest white paper.

Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.

The 2024 Bionow Awards dinner marked an exceptional evening of recognition and celebration, as 342 distinguished guests gathered at the Concorde Conference Centre on 6 March to honour those who have demonstrated outstanding ingenuity and dedication.

TRIMTECH Therapeutics raises $31 million seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases.

Last week was a big one for UK life sciences, from the BIA Committee Summit shaping our sector’s future to major leadership changes at UKRI and NHS England. In this week’s update, I explore what these developments mean for our industry, alongside breakthroughs in AI, investment, and accessibility in healthcare.

In this blog, Albert Maguire - King, Media and Communications Executive at the BIA, outlines how the #BIGIMPACT campaign is utilising AI, data science, and tech talent to drive breakthroughs in biotech—ensuring the UK remains at the cutting edge of healthcare and scientific progress.

Rare Disease Day marks an important occasion to raise awareness of rare diseases and the need for action to support people and families living with these conditions.

Brainomix has announced a strategic partnership with Medtronic Neurovascular, a global leader in medical technology.

Stablepharma Ltd has secured a €2.5 million EIC Accelerator grant, recognizing its pioneering fridge-free pharmaceutical technology.

The data the biotech industry generates, consumes and shares is very often not only extremely sensitive (expensive to create, the product of some of the finest minds and technically focused facilities on the earth, in some cases connectable to the very fabric of humanity), it’s impossible to de-sensitise once lost to an attacker. 

Eleven early-stage companies working in oncology have started ‘Discovery Spark’, a free seven week development programme hosted by leading science and innovation campus Discovery Park, in Sandwich, Kent.

Apprenticeships offer a cost-effective way to develop talent, bridge skills gaps, and drive business growth—find out how they can deliver real ROI for your organisation.

This latest research builds upon the growing body of evidence demonstrating the unique impact of Brainomix’s AI-powered software to expand access to life-changing stroke treatments across networks.

Precision BioSearch is proud to support the Pioneer Group Launch Accelerator Programme for the second consecutive year, equipping the UK and Ireland’s most promising biotech founders with the skills to build and scale high-performing teams.

As Donald Trump returns to the White House, the biotech industry is assessing what his presidency means for investment and innovation. With the UK’s life sciences sector gaining strength, could this be the moment to turn uncertainty into opportunity?